The results are ground-breaking Alpha-Synuclein and Multiple System Atrophy. The often misdiagnosed as Parkinson’s, Multiple System Atrophy (MSA) is a rapidly progressive, fatal neurodegenerative disorder. The disease typically affects individuals between the age of 50 and 75 years of age and is characterized by a combination of autonomic … [Read more...]


The results are ground-breaking ICB International, Inc., (“ICBII”), has moved closer to halting Parkinson’s disease in patients. The Company has shown that its drug halts Parkinson’s disease in animals, which is dose dependent. For example, animals treated with only two doses, one weekly dose for two weeks, showed up to a 17% decrease in the … [Read more...]

June Update on Parkinson’s “Road to the Cure Project”

UPDATE ON PARKINSON’S “ROAD TO THE CURE” PROJECT John looked out the window, remembering better days. He could smell the scent of freshly baked banana nut bread and hear the laughter of his children when they ran out of the kitchen with their mother’s apron over their heads. He could see her smile as she walked into the room, handing him the … [Read more...]

May Update on Parkinson’s  “Road To The Cure” Project

  Why Stem Cell therapy may NOT be the answer And stem-cell therapies have been associated with other adverse effects as well... such adverse effects are probably more common than is appreciated, because there is no reporting requirement…   USFDA CLARIFIES STEM-CELL THERAPY’S BENEFITS AND RISKS [The New England Journal of … [Read more...]

Update on Parkinson’s “Road to the Cure” Project

  The Battle Against Parkinson’s Disease According to Ram Bhatt, PhD, CSO “ICBI continues to make progress in bringing its Parkinson’s drug nearer and nearer to closing the gap between today and delivering it to the people…” It is very encouraging news that the U.S. Food and Drug Administration (FDA) has approved a new drug called … [Read more...]